Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti‐TNF agent: a multicentre cohort study
Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti‐TNF agent: a multicentre cohort study is a paper indexed in PICO Portal from OpenAlex.
How many citations does Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti‐TNF agent: a multicentre cohort study have?
Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti‐TNF agent: a multicentre cohort study has 47 citations in the OpenAlex counts PICO Portal stores.
When was Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti‐TNF agent: a multicentre cohort study published?
Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti‐TNF agent: a multicentre cohort study has 2020 year in the PICO Portal index.
What is the open-access status of Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti‐TNF agent: a multicentre cohort study?
Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti‐TNF agent: a multicentre cohort study has closed oa status in the PICO Portal index.
What is the DOI of Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti‐TNF agent: a multicentre cohort study?
The DOI for Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti‐TNF agent: a multicentre cohort study is on the source record.
What is the PMID of Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti‐TNF agent: a multicentre cohort study?
The PMID for Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti‐TNF agent: a multicentre cohort study is on the source record.
What is the OpenAlex record for Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti‐TNF agent: a multicentre cohort study?
The OpenAlex for Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti‐TNF agent: a multicentre cohort study is on the source record.